Cdt Equity Inc. · NASDAQ:CDT
Cdt Equity — Conduit Pharmaceuticals — SPAC Merger (November 2022)
29 slides from Cdt Equity's SPAC merger presentation, Nov 8, 2022
Slide 1: Conduit Pharma Corporate Presentation
Conduit Pharma CORPORATE PRESENTATION November 2022 ‘CONDUIT PHARMACEUTICALS LIMITED.
Slide 2: Disclaimer
DISCLAIMER Conduit Pharma Use of this investor presentation (“Investor Presentation”) is governed by the terms of the previously executed Confidentiality Agreement which strictly limits the use, circulation and copying of the information embodied herein. Any person in possession of this Investor Pre
Slide 3: Disclaimer (Cont'd)
DISCLAIMER (Cont'd) Conduit Pharma This Investor Presentation is for information purpose and does not constitute an offer to sell, a solicitation of any offer to buy, or a recommendation to purchase any equity, debt or other financial instruments of Conduit, Murphy Canyon or any of their affiliates.
Slide 4: Disclaimer (Cont'd) Additional Information
DISCLAIMER (Cont’d) Conduit Pharma Additional Information In connection with the business combination, Murphy Canyon intends to file with SEC a Registration Statement on Form S-4 (the “Registration Statement”), which will include a preliminary prospectus and preliminary proxy statement. Murphy Canyo
Slide 5: Disclaimer (Cont'd) Forward Looking Statements
DISCLAIMER (Cont’d) Conduit Pharma Cautionary Statement Regarding Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Murphy Canyon and Conduit. All statements othe
Slide 6: Table of Contents
TABLE OF CONTENTS Introduction Asset Pipeline Case Study — SpringWorks Therapeutics Appendix
Slide 7: Introduction
‘CONDUIT PHARMACEUTICALS LIMITED.
Slide 8: Transaction Summary
TRANSACTION SUMMARY Conduit Pharma Transaction Structure * Conduit Pharmaceuticals Limited (“Conduit”) to combine with Murphy Canyon Acquisition Corp. (“Murphy”), a publicly-listed Special Purpose Acquisition Corporation (“SPAC”), with approximately $136.04 MM cash currently held in trust! Valuation
Slide 9: Transaction Summary: Sources, Uses and Pro Forma Valuation
TRANSACTION SUMMARY Conduit Pharma Illustrative Sources (2) ‘© Forma Valuation | Conduit Equity®) $650.00 Share Price ($/sh.) $10.00 SPAC Cash in Trust (4) 136.04 Pro Forma Shares Outstanding 2@) 84.99 | PIPE Cash @) 27.00 Implied Equity Value $849.85 Total Sources $813.04 (+) Debt (4) 0.00 (-) Pro
Slide 10: Summary
SUMMARY Formed in 2019, Conduit is a private company led by a group of highly experienced Pharma and Financial executives, established to fund the development of clinical assets licensed from large pharmaceutical companies, through its exclusive relationships * Conduit takes deprioritized assets fro
Slide 11: Dr. Freda Lewis-Hall, Chair of the Board
DR. FREDA LEWIS-HALL, CHAIR OF THE BOARD Conduit Pharma Dr. Freda Lewis-Hall, Chair of the Board of Directors During her 35-year career in medicine, Dr. Freda Lewis-Hall served as Pfizer, Inc.'s Chief Medical Officer and Executive Vice President until the end of 2018 and as Chief Patient Officer and
Slide 12: Dr. David Tapolczay, Chief Executive Officer
DR. DAVID TAPOLCZAY, CHIEF EXECUTIVE OFFICER Conduit Pharma Dr. David Tapolczay, Chief Executive Officer Prior to joining the charity St. George Street Capital as Chief Executive Officer and a trustee, Dr. David Tapolczay held senior leadership positions at Senior Vice President or CEO level in inte
Slide 13: Our Wider Team
OUR WIDER TEAM Experienced industry professionals responsible for delivering completed clinical trials Jamie Chorlton, Head of Clinical Development Jamie has run >100 clinical trials in industry and within CROs, with 4 therapies progressing to MA. He was recently CEO of a successful CRO (Altair). He
Slide 14: Murphy Canyon Leadership Team
MURPHY CANYON LEADERSHIP TEAM Jack K. Heilbron, Chief Executive Officer & President CEO and President of Presidio Property Trust Inc. (NASDAQ: SQFT) - Former CEO and/or President: - NetREIT Advisors, LLC - Dubose Advisors, LLC — NTR Property Mgt, Inc. * Chairman and CEO of Centurion Counsel, Inc. Ad
Slide 15: Strategic Structure
STRATEGIC STRUCTURE Conduit Pharma Conduit Pharma Astrazeneca? ~» sS . ~ ¢ e . ~ ¢ ¢ ~ ~ ¢ ¢ ~ . ¢ ¢ ~ » yy e ~ » 4 Conduit intends to off * » -* ¢ onduit Intends ae er Sia “ae wv AstraZeneca licences assets Bt cll i eri to St. George Street and retains first rom the: sUccessiul completion Ss T righ
Slide 16: Conduit Pharma & St. George Street (Charity)
CONDUIT PHARMA & ST. GEORGE STREET (CHARITY) Conduit Pharma Conduit Pharma x * Conduit has an exclusive relationship and partnership with St. George Street Capital, where Conduit funds the development of clinical assets acquired (initially) from AstraZeneca * Conduit intends to offer economic return
Slide 17: Large Pharma - AstraZeneca
LARGE PHARMA - ASTRAZENECA Conduit Pharma Conduit Pharma x AstraZeneca * AstraZeneca licenses assets to St. George Street (Charity) who has an exclusive funding relationship with Conduit + AstraZeneca receives: - Positive CSR and off-balance sheet financing for assets with potential for late upside
Slide 18: Asset Pipeline
. — /) ASSET PIPELINE
Slide 19: Overview
OVERVIEW Conduit Pharma | | Current AZ Further Further Agreement: Secured Further Assets Under AstraZeneca Two Assets Licensed Indications on Review From Assets in Six Indications Existing Assets Major Pharma in Discussion 1. AZD5904 in Idiopathic 7. Pulmonary Arterial 15. Sickle Cell Disease * (9As
Slide 20: AZD1656 in COVID-19
AZD1656 in COVID-19 The Problem * Urgent medical need with COVID-19 pandemic with limited treatment available * Second stage of disease is mainly caused by hyperinflammation and AZD1656 employs a novel mechanism to reduce inflammation of many immune pathways ARCADIA Clinical Trial * The ARCADIA clin
Slide 21: AZD1656 in Uveitis
Uveitis Uveitis is an autoimmune disease of the eye that refers to a number of intraocular inflammatory conditions. Uveitis can occur either as a co-manifestation of various autoimmune disorders and infections or as a side effect of medications or it can arise asa purely idiopathic ocular inflammati
Slide 22: AZD5904 in Idiopathic Male Infertility
AZD5904 IN IDIOPATHIC MALE INFERTILITY Conduit Pharma The Problem Growing condition: 48.5m (15%) couples globally are infertile. erry ey] f gesssseeep Significant unmet need in IMI There is currently no approved Both male patients and posnenn > their partners want pharmacotherapy pharmacotherapies f
Slide 23: Idiopathic Male Infertility (IMI)
IDIOPATHIC MALE INFERTILITY (IMI) Conduit Pharma ¢ The total cost of the IMI program is estimated at ~$18 MM ¢ There is no incumbent competition in IMI and nothing in late-stage development. This condition has attracted a large amount of public interest in recent months. If the trial is successful,
Slide 24: Pipeline Valuation
PIPELINE VALUATION | indication | Torin uy pies: i aad ti debe Idiopathic Male Infertility Hashimoto's Thyroiditis Renal Transplant COVID-19 Uveitis Psoriasis Crohn's Disease Diabetic Wound Healing Lupus Sarcoidosis Glioma Pre-Term Labor NOTES: 1._ Investment required for Phase II Clinical Study is
Slide 25: Case Study
Slide 26: SpringWorks Therapeutics
SPRINGWORKS THERAPEUTICS SpringWorks: THERAPEUTICS * SpringWorks Therapeutics is a clinical-stage targeted oncology company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations * SpringWorks was founded in col
Slide 27: Appendix
Slide 28: ARCADIA Phase II Clinical Trial Results
ARCADIA PHASE II CLINICAL TRIAL RESULTS Conduit Pharma * St. George Street Capital, a UK-based biomedical charity, is pleased to announce the completion of the Clinical Study Report from the ARCADIA Phase II clinical trial which was conducted to assess a therapy that could treat diabetic patients su
Slide 29: Conduit Pharma
Conduit Pharma ¥ [email protected] CCONDUMT PHARMACEUTICALS LIMITED :conduitpharma.com
Conduit Pharmaceuticals — SPAC Merger (November 2022) on 6ix